Ramasastry Saira's Form 4 filing
Mirum Pharmaceuticals, Inc.MIRM · filed Sep 10, 2025
- Accession no.
- 0001415889-25-024128
- Filed
- Sep 10, 2025
- Trade date
- Sep 8, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ramasastry SairaCIK 0001547959 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 8, 2025 | Common Stock | MOption exerciseAcquired | +17,000 | $23.51 | +$399,670 | 17,000 | Direct | |
| Sep 8, 2025 | Common Stock | SSaleDisposed | −17,000 | –F1 | – | 0 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 8, 2025 | Common Stock | MOption exerciseDisposed | −17,000 | $0.00 | $0 | 17,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The weighted average sale price for the transaction reported was $77.042178, and the range of prices were between $76.835 and $77.29. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Referenced by the price of 1 transaction in Table I.